** Shares of drug developer Liquidia LQDA.O rise 17.9% to $25 premarket
** Co reports Q2 total revenue of $8.84 mln, compared with analysts' estimates of $4.05 mln, as per LSEG data
** Co says its inhaled drug to treat blood pressure, Yuterpia, surpasses 900 patient prescriptions and 550 patient starts within 11 weeks after FDA approval
** This initial demand has exceeded my own high expectations- CEO Roger Jeffs
** On May 23, the U.S. FDA approved Yutrepia inhalation powder to treat adults diagnosed with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease
** Co had cash and cash equivalents of $173.4 million as of June 30, 2025, compared with $176.5 million as of December 31, 2024
** Up to last close, stock up 80.3% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.